靶向抑制PD-L1/PD-1的免疫治疗恶性黑色素瘤新进展

鹿玉印, 郭秀丽

中国药学杂志 ›› 2015, Vol. 50 ›› Issue (22) : 1931-1935.

PDF(931 KB)
PDF(931 KB)
中国药学杂志 ›› 2015, Vol. 50 ›› Issue (22) : 1931-1935. DOI: 10.11669/cpj.2015.22.001
综 述

靶向抑制PD-L1/PD-1的免疫治疗恶性黑色素瘤新进展

  • 鹿玉印, 郭秀丽*
作者信息 +

Advance Development of Immunotherapy on Malignant Melanoma with Targeting Inhibition of PD-L1/PD-1

  • LU Yu-yin, GUO Xiu-li*
Author information +
文章历史 +

摘要

恶性黑色素瘤具有转移早、进展快、预后差、死亡率高等特点,对于临床医生来说是一个非常大的挑战。当前治疗转移性黑色素瘤的医学手段也因这些特点应用有限。近年来随着免疫治疗晚期黑色素瘤机制的深入研究,一大批治疗恶性黑色素瘤的抗体药物进入临床研究阶段。特别是2014年新型免疫药物抗程序性死亡配体(PD-L1)/程序性死亡受体-1抗体药物pembrolizumab 和nivolumab 顺利通过Ⅲ期临床试验先后被FDA批准上市, 为那些不可切除的或转移的晚期黑色素瘤患者带来了生存的希望。笔者就抗程序性死亡配体-1/程序性死亡受体-1抗体药物治疗黑色素的现状及进展作一综述,为黑色素瘤的新药开发和临床治疗提供参考。

Abstract

Malignant melanoma presents a significant therapeutic challenge to clinicians with characteristics of early metastasis, rapid development, poor prognosis and high mortality. Many therapies for metastatic melanoma are limited by these characteristics. With the development of immunotherapy mechanism for malignant melanoma, a large number of antibody agents for the treatment of malignant melanoma entered the clinical trials. To our great delight, the new drugs of pembrolizumab and nivolumab have been approved by FDA in 2014 after successfully passing phase Ⅲ clinical trial, which bring a chance of survival to patients with unresectable or metastatic advance melanoma. This review briefly discusses recent development and advances of anti-PD-L1/PD-1 antibody drugs against melanoma.

关键词

黑色素瘤 / 免疫治疗 / 抗程序性死亡受体-1抗体药物 / 抗程序性死亡配体-1抗体药物

Key words

melanoma / immunotherapy / anti-PD-1 antibody agent / anti-PD-L1 antibody agent

引用本文

导出引用
鹿玉印, 郭秀丽. 靶向抑制PD-L1/PD-1的免疫治疗恶性黑色素瘤新进展[J]. 中国药学杂志, 2015, 50(22): 1931-1935 https://doi.org/10.11669/cpj.2015.22.001
LU Yu-yin, GUO Xiu-li. Advance Development of Immunotherapy on Malignant Melanoma with Targeting Inhibition of PD-L1/PD-1[J]. Chinese Pharmaceutical Journal, 2015, 50(22): 1931-1935 https://doi.org/10.11669/cpj.2015.22.001
中图分类号: R965   

参考文献

[1] World Health Organization (2013) Skin cancers[OL]. http://www.who.int/uv/faq/skincancer/en/ index1.html.
[2] FREEMAN-KELLER M, WEBER J S. Anti-programmed death receptor 1 immunotherapy in melanoma: Rationale, evidence and clinical potential [J]. Ther Adv Med Oncol, 2015, 7(1): 12-21.
[3] FERLAY J, STELIAROVA-FOUCHER E, LORTET-TIEULENT J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012 [J]. Eur J Cancer, 2013, 49(6): 1374-1403.
[4] CSCO Melanoma Committee. Melanoma Diagnosis and Treatment Guidelines of China(中国黑色素瘤诊疗指南(2013版))[M]. Version 2013. Beijing: People′s Medical Publishing House, 2013:17-18.
[5] JANG S, ATKINS M B. Treatment of BRAF-mutant melanoma: The role of vemurafenib and other therapies [J]. Clin Pharmacol Ther, 2014, 95(1): 24-31.
[6] GIROTTI M R, SATURNO G, LORIGAN P, et al. No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients [J]. Mol Oncol, 2014, 8(6): 1140-1158.
[7] SALAMA A K, FLAHERTY K T. BRAF in melanoma: Current strategies and future directions [J]. Clin Cancer Res, 2013,19(16): 4326-4334.
[8] HOAG H. Drug development: A chance of survival [J]. Nature, 2014, 515(7527):118-120.
[9] SCHADENDORF D, HODI F, ROBERT C, et al. Pooled analysis of long-term survival data from Phase Ⅱ and Phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [J]. Eur J Cancer, 2013,49(suppl 2): abstract 24LBA.
[10] WOLCHOK J D, KLUGER H, CALLAHAN M K, et al. Nivolumab plus ipilimumab in advanced melanoma [J]. N Engl J Med, 2013, 369(2):122-133.
[11] REICHERT J M. Antibodies to watch in 2015 [J]. MAbs, 2015, 7(1): 1-8.
[12] TAUBE J M, ANDERS R A, YOUNG G D, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape [J]. Sci Transl Med, 2012,4(127): 127-137.
[13] MOMTAZ P, POSTOW M A. Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway [J]. Pharmgenomics Pers Med, 2014, 15(7):357-365.
[14] KYI C, POSTOW M A. Checkpoint blocking antibodies in cancer immunotherapy [J]. FEBS Lett, 2014, 588 (2): 368-376.
[15] POOLE R M. Pembrolizumab: First global approval [J]. Drugs, 2014, 74(16):1973-1981.
[16] HAMID O, ROBERT C, DAUD A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma [J]. N Engl J Med, 2013, 369(2):134-144.
[17] HERSEY P, GOWRISHANKAR K. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma [J]. Future Oncol, 2015, 11(1):133-140.
[18] TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med, 2012, 366(26):2443-2454.
[19] TOPALIAN S L, SZNOL M, MCDERMOTT D F, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab [J]. J Clin Oncol, 2014, 32(10):1020-1030.
[20] ATKINS M B, KUDCHADKAR R R, SZNOL M, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma [J]. J Clin Oncol, 2014, 32(suppl): abstract 9001.
[21] INFANTE J R, POWDERLY J D, BURRIS H A, et al. Clinical and pharmacodynamics (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor [J]. J Clin Oncol, 2014, 31(suppl): abstract 3044.
[22] HERBST R S, GORDON M S, FINE G D, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [J]. J Clin Oncol, 2013, 31(suppl): abstract 3000.
[23] HAMID O, SOSMAN J A, LAWRENCE D P, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic melanoma [J]. J Clin Oncol, 2013, 31(suppl): abstract 9010.
[24] KHLEIF S, LUTZKY J, SEGAL N, et al. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase I study in patients with advanced solid tumors [OL]. European Cancer Congress, 2013, Sep 27-Oct 1: abstract 802.
[25] LUTZKY J, ANTONIA S, BLAKE-HASKINS A, et al. A phase 1 study of MEDI4736, an antiePD-L1 antibody, in patients with advanced solid tumors[J]. J Clin Oncol, 2014, 32 (suppl): abstract 3001.
[26] BRAHMER J R, TYKODI S S, CHOW L Q, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J]. N Engl J Med, 2012, 366(26): 2455-2465.
[27] TYKODI S S, BRAHMIER J R, HWU W J, et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors [J]. J Clin Oncol, 2012, 30(suppl) abstract, 2510.
[28] HEERY C R, COYNE G H, MADAN R A, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies [J]. J Clin Oncol, 2014, 32(Suppl): abstract 3064.
[29] POWDERLY J, KOEPPEN H, HODI F, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study [J]. J Clin Oncol, 2013, 31(suppl): abstract 3001.
[30] KAUFMAN H L, KIRKWOOD J M, HODI F S, et al. 2013. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma [J]. Nat Rev Clin Oncol, 2013, 10(10): 588-598.

基金

国家自然科学基金资助项目(81373450)
PDF(931 KB)

168

Accesses

0

Citation

Detail

段落导航
相关文章

/